Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

R2530

Sigma-Aldrich

Ropinirole hydrochloride

powder, ≥98% (HPLC)

Synonyme(s) :

4-[2-(Dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one hydrochloride, SKF 101468 hydrochloride

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C16H24N2O · HCl
Numéro CAS:
91374-20-8
Poids moléculaire :
296.84
Numéro MDL:
MFCD01754173
Code UNSPSC :
12352200
ID de substance PubChem :
329824018
Nomenclature NACRES :
NA.77

Pureté

≥98% (HPLC)

Forme

powder

Conditions de stockage

desiccated

Couleur

light yellow

Solubilité

H2O: >10 mg/mL

Auteur

GlaxoSmithKline

Chaîne SMILES 

Cl.CCCN(CCC)CCc1cccc2NC(=O)Cc12

InChI

1S/C16H24N2O.ClH/c1-3-9-18(10-4-2)11-8-13-6-5-7-15-14(13)12-16(19)17-15;/h5-7H,3-4,8-12H2,1-2H3,(H,17,19);1H

Clé InChI

XDXHAEQXIBQUEZ-UHFFFAOYSA-N

Informations sur le gène

human ... DRD2(1813) , DRD3(1814) , DRD4(1815)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Actions biochimiques/physiologiques

An agonist at the D2 and D3 dopamine receptor subtypes, binding with higher affinity to D3 than to D2 or D4. It has negligible effect on D1-receptors. It has medium in vitro affinity to opioid receptors. Ropinirole is said to have virtually no affinity to 5-HT1, 5-HT2, benzodiazepine, GABA, muscarinic, α1-, α2-, and β-adrenoreceptors. Used as antiparkinsonian drug.
Ropinirole hydrochloride is effectively used to treat early and late Parkinson′s disease.

Caractéristiques et avantages

This compound is featured on the Dopamine Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictogrammes

Exclamation markEnvironment
GHS07,GHS09

Mention d'avertissement

Warning

Mentions de danger

H302,H400

Classification des risques

Acute Tox. 4 Oral - Aquatic Acute 1

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Équipement de protection individuelle

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Francisco J Zagmutt et al.
The International journal of neuroscience, 122(7), 345-353 (2012-02-07)
The comparative safety profiles of monotherapeutic treatments for Parkinson's disease (PD) can provide valuable therapeutic information. The objective of this study was to perform an indirect comparison of Adverse Events (AEs) and Dropout Rates (DRs) among clinical trials of pramipexole
N Hattori et al.
Journal of clinical pharmacy and therapeutics, 37(5), 571-577 (2012-03-07)
Ropinirole hydrochloride, a dopamine receptor agonist with a non-ergot alkaloid structure, is highly selective for the dopamine D(2) /D(3) receptors. This study was conducted to evaluate the steady-state pharmacokinetics, safety and efficacy after repeated oral administration of prolonged-release tablets of
Dopamine agonist withdrawal syndrome in a patient with restless legs syndrome.
Benjamin J Dorfman et al.
Parkinsonism & related disorders, 19(2), 269-270 (2012-07-04)
T Nissen et al.
Scottish medical journal, 57(4), 217-220 (2012-09-25)
The expected duration of initial antiparkinson monotherapy before the need for supplementation is not clearly defined for routine practice. The aim of this study was to define the length of L-dopa (L-3, 4-dihydrophenylalanine) and dopamine agonist monotherapy. The duration of
Carlo Tessa et al.
Parkinsonism & related disorders, 19(2), 265-268 (2012-08-21)
Previous fMRI studies indicated a relationship between changes of the cortical activation pattern and disease severity in Parkinson's disease (PD). Early diagnosis of Parkinson's disease offers the opportunity to evaluate the putative neuroprotective and disease-modifying effects of drugs at a
Afficher tous les articles scientifiques apparentés

Articles

Dopamine Receptors

We offer many products related to dopamine receptors for your research needs.

Dopamine Receptors

We offer many products related to dopamine receptors for your research needs.

Dopamine Receptors

We offer many products related to dopamine receptors for your research needs.

Dopamine Receptors

We offer many products related to dopamine receptors for your research needs.

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique